NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 41 min 29 sec ago

Genomic Predictors of Pregnancy Loss (R01 Clinical Trial Not Allowed)

Thu, 2020-03-19 11:28
Funding Opportunity RFA-HD-21-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support studies which utilize emerging genomic technologies to identify variants which predict risk for pregnancy loss in subsequent pregnancies beyond standard karyotype approaches.

Notice of Information: Leveraging STRIDES for Cloud Computing Activities in Common Fund Awards

Thu, 2020-03-19 03:13
Notice NOT-RM-20-009 from the NIH Guide for Grants and Contracts

Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed)

Thu, 2020-03-19 02:19
Funding Opportunity RFA-HG-20-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications from small businesses to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.

Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)

Thu, 2020-03-19 02:15
Funding Opportunity RFA-HG-20-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)

Thu, 2020-03-19 02:10
Funding Opportunity RFA-HG-20-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable no less than one order of magnitude improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs (e.g., longer oligonucleotide and synthetic construct lengths, faster turn-around times, greater accuracy, incorporation of modified bases, higher-throughput, etc.) at reasonable and decreased costs with the anticipation that major advances in any of these and related areas would make significant contributions to the mission of NIH, NHGRI and the field of genomics, including to many of NHGRIs other technology development goals.

Patient-oriented Research to Mitigate Health Disparities and Lessen the Burden of Chronic Diseases Within the Mission of NIDDK (R01 Clinical Trial Optional)

Wed, 2020-03-18 11:15
Funding Opportunity RFA-DK-20-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications to conduct patient-oriented clinical research studies designed to develop strategies to mitigate health disparities in people with one or more chronic diseases or conditions within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Populations of interest include those disproportionately burdened with multiple chronic conditions and/or disparities in social, behavioral and/or biological risk factors. Only studies that involve interaction with human participants will be considered appropriate for this FOA.

Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19

Tue, 2020-03-17 13:13
Notice NOT-OD-20-088 from the NIH Guide for Grants and Contracts

Pages